Abstract: Healthcare professionals’ perceptions of the impact on clinical management of switching from the intravenous to the subcutaneous formulation of trastuzumab

 

Abstract: Healthcare professionals’ perceptions of the impact on clinical management of switching from the intravenous to the subcutaneous formulation of trastuzumab

The international, randomised, two-cohort PrefHer study (NCT01401166) assessed patients’ preferences for subcutaneous trastuzumab (Herceptin® SC, F. Hoffmann-La Roche Ltd, Basel, Switzerland) via single-use injection device (SID, Cohort 1)1 or the European Medicines Agency (EMA)-approved hand-held syringe (Cohort 2)2 vs intravenous (IV) trastuzumab in HER2-positive early breast cancer.